Eli Lilly and Company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Eli Lilly and Company sits in the top decile of US sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count).
Eli Lilly and Company: 1,341 sponsored US clinical trials, 124 recruiting.
Eli Lilly and Company sponsors 1,341 registered US clinical trials on ClinicalTrials.gov, 124 of them currently recruiting, and 1,029 completed. 459 of these trials are in Phase 3-4 (later-stage) and 861 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 55 trials.
Top-decile sponsor footprint
Eli Lilly and Company ranks in the top decile of sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,029 of 1,131 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,341 total, page 18 of 27
An Open Label Study for Participants With Rheumatoid Arthritis
NCT01215942
A Study in Prevention of Re-emergence of Depression Symptoms
NCT01299272
A Study of LY2495655 in Healthy Subjects
NCT01341470
A Study in Participants With End-Stage Renal Disease
NCT01200290
Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
NCT01282463
A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer
NCT01246960
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
NCT01059643
A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma
NCT01220271
A Study in Non-Small Cell Lung Cancer
NCT01232452
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
NCT01246986
A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors
NCT01288989
A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome
NCT01237587
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
NCT01185340
Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
NCT01234402
A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
NCT01187407
A Study of the Effect of LY2189265 on Two Blood Pressure Drugs
NCT01324388
Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin
NCT01136746
A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.
NCT01301092
Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects
NCT01299285
A Study of LY2409021 in Patients With Type 2 Diabetes
NCT01241448
Disposition of 14C-LY2452473 Following Oral Administration in Healthy Human Subjects
NCT01275157
A Rheumatoid Arthritis Study in Participants
NCT01202760
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
NCT01205438
A Study in Migraine Prevention
NCT01184508
A Study in Participants With Rheumatoid Arthritis
NCT01202773
A Study in Second Line Metastatic Colorectal Cancer
NCT01183780
A Study of LY2216684 and Digoxin in Healthy Subjects
NCT01266590
A Safety Study of LY2886721 Multiple Doses in Healthy Subjects
NCT01227252
A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol
NCT01263197
A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma
NCT01170663
Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes
NCT01215955
A Study of Brain Receptor Occupancy in Healthy Subjects
NCT01232439
A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy
NCT01168973
A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel
NCT01263093
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
NCT01196091
A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors
NCT01263223
A Study of LY2216684 and Warfarin in Healthy Subjects
NCT01263119
A Study of LY2216684 and Theophylline in Healthy Subjects
NCT01263106
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
NCT01127633
A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate
NCT01198002
A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline
NCT01250873
A Study of LY3009104(Baricitinib) for Healthy Subjects
NCT01247350
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
NCT01173601
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)
NCT01191268
A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women
NCT01250145
A Study in Participants With Acute Leukemia
NCT01214603
A Study of LY2608204 in Patients With Type 2 Diabetes
NCT01247363
A Study of LY2216684 in Participants With Impaired Hepatic Function
NCT01241435
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib
NCT01140347
A Safety Study in Participants With Major Depressive Disorder
NCT01155661
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 517 |
| Phase 2 | 344 |
| Phase 3 | 368 |
| Phase 4 | 91 |
Therapeutic Areas
What is open in the Eli Lilly and Company pipeline
124 recruiting of 1,341 indexed (9% open); 1,029 completed (77%).
Phase mix: 459 late (III/IV) vs 861 early (I/II) (early-phase heavy).
Top condition: Healthy (55 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Eli Lilly and Company: open-pipeline peers nationwide
Peers matched on 1,341 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Eli Lilly and Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,341 trials (± recruiting share)
- GlaxoSmithKline · 1,345 trials · 4% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
- AstraZeneca · 1,285 trials · 12% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Shionogi · 9% recruiting · 54 trials
- University of Kentucky · 9% recruiting · 54 trials
- University of Vermont · 9% recruiting · 162 trials
- Lahey Clinic · 9% recruiting · 43 trials
Related
What to do with this Eli Lilly and Company page
1,341 registered trials is a research-attention snapshot, not an endorsement of Eli Lilly and Company or any single study.
- 124 of Eli Lilly and Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Eli Lilly and Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Eli Lilly and Company pipeline card: 1,341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.